Compare Amgen, Inc. (AMGN) vs Tencent Music Entertainment Group - ADR (TME) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Amgen, Inc. vs Tencent Music Entertainment Group - ADR — how do they compare? Amgen, Inc. trades at $363.55 (market cap $196.12B), while Tencent Music Entertainment Group - ADR trades at $8.85 (market cap $14.63B). The key difference: Amgen, Inc. is far larger — about 13.4× Tencent Music Entertainment Group - ADR's market cap, and Amgen, Inc. pays the higher dividend (2.77%). Which is the better fit depends on your goals.
| AMGN | TME | |
|---|---|---|
Market Cap | $196.12B | $14.63B |
Sector | Health | Media |
52-Week High | $388.16 | $26.36 |
52-Week Low | $271.18 | $8.16 |
Enterprise Value | $241.41B | $11.41B |
Dividend Yield | 2.77% | 2.7% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMGN trades at $363.39, down slightly by 0.06% today, with a bullish technical signal from moving averages. The company reported strong Q1 2026 earnings, beating estimates with EPS of $5.15 versus $4.77 expected. Revenue grew to $36.75B in 2025, with a net income margin of 20.96%. Recent news includes a favorable court ruling blocking a price cap on Enbrel in Colorado, but regulatory challenges persist for Tavneos in Europe.
The outlook remains positive due to consistent earnings beats and a diversified product portfolio, though risks include regulatory setbacks and competitive pressures. Analyst consensus is bullish with a 57.9% buy rating and a price target of $357.38, slightly below the current price, indicating potential for stability with upside from pipeline developments.
TME trades at $8.88, up 0.34% today, with a bullish technical signal despite recent earnings misses. The stock shows strong fundamentals with a P/E of 10.63 and net income margin of 26.48% for 2025. Revenue grew to $32.90B in 2025, though Q2 2026 EPS is expected at $0.24. Analyst consensus is mixed with a $14.00 price target. Recent news highlights strategic moves like the Ximalaya acquisition and partnerships, though competition remains a concern.
The outlook for TME is cautiously optimistic with solid profitability and valuation support, but near-term growth faces headwinds from competition and AI-related challenges. Investors should weigh the attractive margins against execution risks and market sentiment shifts for balanced exposure.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →About Tencent Music Entertainment Group - ADR
TME is the largest online music service provider in China. It was founded in 2016 with the business combination of QQ Music (founded in 2005), Kuwo Music (founded in 2005) and Kugou Music (founded in 2004) streaming platforms. Tencent is the largest shareholder of TME with over 50% shares and over 90% voting rights held. TME also provides social entertainment services, including music live audio/video broadcasts and online concert services through the three platforms mentioned above, and online karaoke through an independent platform WeSing.
Read more on TME →
